As such, apoC-III is a target for a new class of drugs aimed to lower triglyceride levels and indirectly preventing cardiovascular incidents and pancreatitis episodes in patients with hypertriglyceridemia. This evidence concerns the gene APOC3 and hypertriglyceridemia.